Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Antigua and Barbuda
Medical Surgical Associates Center, St John's Argentina
Center for Investigation in Tissue Engineering and Cellular Therapy, Buenos Aires